Henry Schein, Inc. (NASDAQ: HSIC) Stock Competitors & Peer Comparison
See HSIC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HSIC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HSIC | $87.52 | -1.59% | 10B | 16.48 | $5.31 | N/A |
| MCK | $899.56 | -1.25% | 105.3B | 22.03 | $40.82 | +0.39% |
| COR | $323.29 | -0.90% | 62.9B | 18.85 | $17.15 | +0.75% |
| CAH | $232.65 | -0.95% | 54.5B | 22.30 | $10.43 | +0.87% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| AHG | $0.76 | -5.21% | 687.4M | -3.77 | -$0.21 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| EMPG | $17.36 | +0.00% | 143M | 192.89 | $0.09 | N/A |
| ACH | $1.13 | +0.45% | 86.2M | 1.65 | $0.68 | N/A |
Stock Comparison
McKesson Corporation (NYSE: MCK)
HSIC vs MCK Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, MCK has a market cap of 105.3B. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while MCK trades at $899.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas MCK's P/E ratio is 22.03. In terms of profitability, HSIC's ROE is +0.12%, compared to MCK's ROE of -1.94%. Regarding short-term risk, HSIC is less volatile compared to MCK. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check MCK's competition here
Cencora, Inc. (NYSE: COR)
HSIC vs COR Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, COR has a market cap of 62.9B. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while COR trades at $323.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas COR's P/E ratio is 18.85. In terms of profitability, HSIC's ROE is +0.12%, compared to COR's ROE of +1.06%. Regarding short-term risk, HSIC is less volatile compared to COR. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check COR's competition here
Cardinal Health, Inc. (NYSE: CAH)
HSIC vs CAH Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, CAH has a market cap of 54.5B. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while CAH trades at $232.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas CAH's P/E ratio is 22.30. In terms of profitability, HSIC's ROE is +0.12%, compared to CAH's ROE of -0.60%. Regarding short-term risk, HSIC is more volatile compared to CAH. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check CAH's competition here
AmerisourceBergen Corporation (NYSE: ABC)
HSIC vs ABC Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas ABC's P/E ratio is 21.92. In terms of profitability, HSIC's ROE is +0.12%, compared to ABC's ROE of +1.06%. Regarding short-term risk, HSIC is more volatile compared to ABC. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check ABC's competition here
Patterson Companies, Inc. (NASDAQ: PDCO)
HSIC vs PDCO Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HSIC's ROE is +0.12%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, HSIC is more volatile compared to PDCO. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check PDCO's competition here
Akso Health Group (NASDAQ: AHG)
HSIC vs AHG Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, AHG has a market cap of 687.4M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while AHG trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas AHG's P/E ratio is -3.77. In terms of profitability, HSIC's ROE is +0.12%, compared to AHG's ROE of -0.50%. Regarding short-term risk, HSIC is less volatile compared to AHG. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check AHG's competition here
Owens & Minor, Inc. (NYSE: OMI)
HSIC vs OMI Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas OMI's P/E ratio is -0.47. In terms of profitability, HSIC's ROE is +0.12%, compared to OMI's ROE of +0.63%. Regarding short-term risk, HSIC is less volatile compared to OMI. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check OMI's competition here
Empro Group Inc. Ordinary shares (NASDAQ: EMPG)
HSIC vs EMPG Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, EMPG has a market cap of 143M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while EMPG trades at $17.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas EMPG's P/E ratio is 192.89. In terms of profitability, HSIC's ROE is +0.12%, compared to EMPG's ROE of +0.66%. Regarding short-term risk, HSIC is more volatile compared to EMPG. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check EMPG's competition here
Accendra Health, Inc. (NYSE: ACH)
HSIC vs ACH Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, ACH has a market cap of 86.2M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while ACH trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas ACH's P/E ratio is 1.65. In terms of profitability, HSIC's ROE is +0.12%, compared to ACH's ROE of +0.63%. Regarding short-term risk, HSIC is less volatile compared to ACH. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check ACH's competition here
Akso Health Group (NASDAQ: HX)
HSIC vs HX Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas HX's P/E ratio is -1.84. In terms of profitability, HSIC's ROE is +0.12%, compared to HX's ROE of -1.07%. Regarding short-term risk, HSIC is less volatile compared to HX. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check HX's competition here
111, Inc. (NASDAQ: YI)
HSIC vs YI Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, YI has a market cap of 29.1M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while YI trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas YI's P/E ratio is -2.38. In terms of profitability, HSIC's ROE is +0.12%, compared to YI's ROE of +0.14%. Regarding short-term risk, HSIC is less volatile compared to YI. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check YI's competition here
Wellgistics Health, Inc. (NASDAQ: WGRX)
HSIC vs WGRX Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, WGRX has a market cap of 8.7M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while WGRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas WGRX's P/E ratio is -0.33. In terms of profitability, HSIC's ROE is +0.12%, compared to WGRX's ROE of +8.78%. Regarding short-term risk, HSIC is less volatile compared to WGRX. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check WGRX's competition here
DataMEDS AI, Inc. (NASDAQ: MEDS)
HSIC vs MEDS Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, MEDS has a market cap of 4.3M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while MEDS trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas MEDS's P/E ratio is N/A. In terms of profitability, HSIC's ROE is +0.12%, compared to MEDS's ROE of +8.78%. Regarding short-term risk, HSIC is less volatile compared to MEDS. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check MEDS's competition here
Zynex, Inc. (NASDAQ: ZYXI)
HSIC vs ZYXI Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, HSIC's ROE is +0.12%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, HSIC is more volatile compared to ZYXI. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check ZYXI's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
HSIC vs HKPD Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, HKPD has a market cap of 1.2M. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while HKPD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas HKPD's P/E ratio is -1.85. In terms of profitability, HSIC's ROE is +0.12%, compared to HKPD's ROE of -0.15%. Regarding short-term risk, HSIC is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check HKPD's competition here
Synergy CHC Corp. (NASDAQ: SNYR)
HSIC vs SNYR Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, SNYR has a market cap of 856.5K. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while SNYR trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas SNYR's P/E ratio is -0.06. In terms of profitability, HSIC's ROE is +0.12%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, HSIC is less volatile compared to SNYR. This indicates lower risk in terms of short-term price fluctuations for HSIC.Check SNYR's competition here
Ridgetech, Inc. (NASDAQ: RDGT)
HSIC vs RDGT Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, RDGT has a market cap of 733.5K. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while RDGT trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas RDGT's P/E ratio is -0.02. In terms of profitability, HSIC's ROE is +0.12%, compared to RDGT's ROE of -0.04%. Regarding short-term risk, HSIC is more volatile compared to RDGT. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check RDGT's competition here
Covetrus, Inc. (NASDAQ: CVET)
HSIC vs CVET Comparison September 2026
Henry Schein, Inc. (NASDAQ: HSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSIC stands at 10B. In comparison, CVET has a market cap of 0. Regarding current trading prices, HSIC is priced at $87.52 on the NASDAQ, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSIC currently has a P/E ratio of 16.48, whereas CVET's P/E ratio is -69.97. In terms of profitability, HSIC's ROE is +0.12%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HSIC is more volatile compared to CVET. This indicates higher risk in terms of short-term price fluctuations for HSIC.Check CVET's competition here